Luye Pharma Group Ltd. (HK:2186)
:2186
Want to see HK:2186 full AI Analyst Report?
Total Valuation
Luye Pharma Group has a market cap or net worth of HK$8.84B. The enterprise value is HK$12.76B.
Market CapHK$8.84B
Enterprise ValueHK$12.76B
Share Statistics
Luye Pharma Group has 3,994,515,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,994,515,900
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Luye Pharma Group’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.13%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.13%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee1.22M
Profits Per Employee183.42K
Employee Count5,150
Asset Turnover0.19
Inventory Turnover2.24
Valuation Ratios
The current PE Ratio of Luye Pharma Group is 8.3. Luye Pharma Group’s PEG ratio is 0.67.
PE Ratio8.3
PS Ratio1.52
PB Ratio0.60
Price to Fair Value0.60
Price to FCF12.29
Price to Operating Cash Flow22.91
PEG Ratio0.67
Income Statement
In the last 12 months, Luye Pharma Group had revenue of 6.31B and earned 618.75M in profits. Earnings per share was 0.16.
Revenue6.31B
Gross Profit4.16B
Operating Income1.24B
Pretax Income944.64M
Net Income618.75M
EBITDA2.01B
Earnings Per Share (EPS)0.16
Cash Flow
In the last 12 months, operating cash flow was 348.56M and capital expenditures 63.69M, giving a free cash flow of 412.24M billion.
Operating Cash Flow348.56M
Free Cash Flow412.24M
Free Cash Flow per Share0.10
Dividends & Yields
Luye Pharma Group pays an annual dividend of HK$0.06, resulting in a dividend yield of ―
Dividend Per ShareHK$0.06
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change8.13%
50-Day Moving Average2.58
200-Day Moving Average3.06
Relative Strength Index (RSI)29.70
Average Volume (3m)38.67M
Important Dates
Luye Pharma Group upcoming earnings date is Aug 27, 2026, TBA (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateAug 27, 2026
Ex-Dividend Date―
Financial Position
Luye Pharma Group as a current ratio of 1.53, with Debt / Equity ratio of 58.59%
Current Ratio1.53
Quick Ratio1.44
Debt to Market Cap0.98
Net Debt to EBITDA2.44
Interest Coverage Ratio1.81
Taxes
In the past 12 months, Luye Pharma Group has paid 238.98M in taxes.
Income Tax238.98M
Effective Tax Rate0.25
Enterprise Valuation
Luye Pharma Group EV to EBITDA ratio is 7.20, with an EV/FCF ratio of 18.59.
EV to Sales2.30
EV to EBITDA7.20
EV to Free Cash Flow18.59
EV to Operating Cash Flow8.14
Balance Sheet
Luye Pharma Group has HK$8.88B in cash and marketable securities with HK$9.42B in debt, giving a net cash position of -HK$541.73M billion.
Cash & Marketable SecuritiesHK$8.88B
Total DebtHK$9.42B
Net Cash-HK$541.73M
Net Cash Per Share-HK$0.14
Tangible Book Value Per ShareHK$2.77
Margins
Gross margin is 65.99%, with operating margin of 19.70%, and net profit margin of 9.81%.
Gross Margin65.99%
Operating Margin19.70%
Pretax Margin14.97%
Net Profit Margin9.81%
EBITDA Margin31.93%
EBIT Margin19.30%
Analyst Forecast
The average price target for Luye Pharma Group is HK$4.32, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetHK$4.32
Price Target Upside43.05% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast4.09%
EPS Growth Forecast27.35%